A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.

Seino, Yutaka; Kaku, Kohei; Kadowaki, Takashi; Okamoto, Taro; Sato, Asako; Shirakawa, Masayoshi; O'Neill, Edward A; Engel, Samuel S; Kaufman, Keith D

Seino, Yutaka; Kaku, Kohei; Kadowaki, Takashi; Okamoto, Taro; Sato, Asako; Shirakawa, Masayoshi; O'Neill, Edward A; Engel, Samuel S; Kaufman, Keith D.

Affiliation

Seino Y; Kansai Electric Power Hospital, Osaka, Japan.
Kaku K; Kansai Electric Power Medical Research Institute, Osaka, Japan.
Kadowaki T; Kawasaki Medical School, Okayama, Japan.
Okamoto T; Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Sato A; Toranomon Hospital, Tokyo, Japan.
Shirakawa M; Japan Development, MSD K.K., Tokyo, Japan.
O'Neill EA; Japan Development, MSD K.K., Tokyo, Japan.
Engel SS; Japan Development, MSD K.K., Tokyo, Japan.
Kaufman KD; Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.

Diabetes Obes Metab ; 23(6): 1342-1350, 2021 06.

Article de En | MEDLINE | ID: mdl-33565686

Sujet(s)
Mots clés

DPP-4 inhibitor; SGLT2 inhibitor; combination therapy; incretins

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Diabète de type 2 / Inhibiteurs de la dipeptidyl-peptidase IV / Metformine Type d'étude: Clinical_trials / Prognostic_studies Limites: Humans / Middle aged Pays/Région comme sujet: Asia Langue: En Journal: Diabetes Obes Metab Sujet du journal: ENDOCRINOLOGIA / METABOLISMO Année: 2021 Type de document: Article Pays d'affiliation: Japon Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google